<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02000830</url>
  </required_header>
  <id_info>
    <org_study_id>64,185-205</org_study_id>
    <nct_id>NCT02000830</nct_id>
  </id_info>
  <brief_title>Follow up Study of Patients Having Participated in Clinical Trial 64,185-204</brief_title>
  <acronym>JASMINE_205</acronym>
  <official_title>A Four-Year Blinded Outcomes Follow-up Study of Patients Who Received Stannsoporfin or Placebo in Clinical Trial 64,185-204</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this follow up study are to evaluate the long-term effects of stannsoporfin
      (Stanate) on the health, growth, and development of patients who received a single dose of
      stannsoporfin with PT used to treat hyperbilirubinemia compared with patients in the control
      (placebo plus PT) group in clinical trial 64,185-204.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outcomes will be based on the following variables:

      Reported AEs and SAEs Hearing assessments Developmental assessments
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2013</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reported adverse events (AEs)</measure>
    <time_frame>48-52 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hearing assessments</measure>
    <time_frame>48 - 52 month</time_frame>
    <description>Conventional audiometry will be performed by a qualified specialist. Any findings from a failed conventional audiology examination will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental assessments</measure>
    <time_frame>48 - 52 month</time_frame>
    <description>The Mullen Scales of Early Learning examination has been selected for its standardized measurement of developmental skills in multiple domains (gross motor, visual reception, fine motor, expressive language, and receptive language). Testing will be done at visits 1 and 2 by a healthcare individual trained to administer the test. The Mullen raw scores, T-scores, and age equivalents will be recorded.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">68</enrollment>
  <condition>Hyperbilirubinemia, Neonatal</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <description>Participants received placebo during the earlier study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stannsoporfin 3.0 mg/kg</arm_group_label>
    <description>Participants received Stannsoporfin 3.0 mg/kg during the earlier study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stannsoporfin 4.5 mg/kg</arm_group_label>
    <description>Participants received Stannsoporfin 4.5 mg/kg during the earlier study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stannsoporfin</intervention_name>
    <description>Stannsoporfin administered by intramuscular (IM) injection</description>
    <arm_group_label>Stannsoporfin 3.0 mg/kg</arm_group_label>
    <arm_group_label>Stannsoporfin 4.5 mg/kg</arm_group_label>
    <other_name>Experimental product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo administered by IM injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who received a single dose of trial medication in clinical trial 64,185-204.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who received IMP (stannsoporfin or placebo) in clinical trial 64,185-204

          -  Parents or guardians have given written informed consent to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>52 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader, MD</last_name>
    <role>Study Chair</role>
    <affiliation>InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company</affiliation>
  </overall_official>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 28, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2013</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stannsoporfin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperbilirubinemia, Neonatal</mesh_term>
    <mesh_term>Hyperbilirubinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tin mesoporphyrin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

